Profitelligence Profitelligence · Filing Ledger Open BDX research →

Form 8-K · Current Report · Filed 2025-11-06

BD Reports Fourth Fiscal Quarter 2025 Financial Results

On November 6, 2025, Becton, Dickinson and Company (BD) announced its financial results for the fourth fiscal quarter ending September 30, 2025.

Filer
Becton, Dickinson and Company BDX · NYSE
Filed
Accession
0001628280-25-049835
CIK
0000010795
Signal
Low impactHealthcare

Details

The press release, which is furnished as Exhibit 99.1, includes non-GAAP financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles. Details regarding these non-GAAP measures and adjustments can be found in the schedules included in the press release.

Items reported

Item 2.02

Results of Operations and Financial Condition

General Statement
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$138.67

Next session

+0.8%

Since filing

+19.4%

Latest close

$165.62

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from BDX reporting the same item, with the next session's move:

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.

Exchange NYSE Industry Medical Instruments & Supplies Company website ↗

Never miss another BDX filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts